Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy. Issue 2 (28th January 2021) - Lee, Sangmin; Desai, Pinkal; Edirisinghe, Bianca; Pianello, Samantha; Curcio, Tania; Samuel, Michael; Ritchie, Ellen K.; Roboz, Gail J.